The invention provides liquid rotavirus formulations that are suitable fororal administration to human infants. In particular the invention providespharmaceutical compositions and vaccines, comprising a rotavirus antigen, asugar and a carboxylate wherein said formulation has a pH of between pH 5.0and pH 8.0 and comprises no phosphate or less than 5 mM phosphate. Theinvention also provides methods of preparing said rotavirus formulations anduse thereof in the prevention or treatment of rotavirus associated diseases inhumans.